Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
May 16, 2015
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
Francesco Ceci, Christian Uprimny, Bernhard Nilica, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 10, 2020
Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients
Christian Uprimny, Steffen Bayerschmidt, Alexander Stephan Kroiss, et al.
Cancers
|
December 23, 2022
A Multi-Disciplinary Approach to Diagnosis and Treatment of Radionecrosis in Malignant Gliomas and Cerebral Metastases
Julian Mangesius, Stephanie Mangesius, Matthias Demetz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 26, 2020
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
Leonhard Gruber, Luis David Jiménez-Franco, Clemens Decristoforo, et al.
Journal of Neuro-Oncology
|
September 14, 2023
Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma
Sarah Iglseder, Anna Iglseder, Vincent Beliveau, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 20, 2014
(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT
Alexander Kroiss, Barry Lynn Shulkin, Christian Uprimny, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 28, 2013
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma
Alexander Kroiss, Daniel Putzer, Andreas Frech, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 8, 2017
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence
Christian Uprimny, Alexander Stephan Kroiss, Josef Fritz, et al.
Biomedicines
|
November 26, 2022
Imaging Properties and Tumor Targeting of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
Leonhard Gruber, Clemens Decristoforo, Christian Uprimny, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 17, 2025
Safety, Biodistribution, and Radiation Dosimetry of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
Elisabeth von Guggenberg, Gianpaolo di Santo, Christian Uprimny, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
European Journal of Nuclear Medicine and Molecular Imaging
|
May 16, 2015
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?
Francesco Ceci, Christian Uprimny, Bernhard Nilica, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 10, 2020
Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients
Christian Uprimny, Steffen Bayerschmidt, Alexander Stephan Kroiss, et al.
Cancers
|
December 23, 2022
A Multi-Disciplinary Approach to Diagnosis and Treatment of Radionecrosis in Malignant Gliomas and Cerebral Metastases
Julian Mangesius, Stephanie Mangesius, Matthias Demetz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 26, 2020
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
Leonhard Gruber, Luis David Jiménez-Franco, Clemens Decristoforo, et al.
Journal of Neuro-Oncology
|
September 14, 2023
Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma
Sarah Iglseder, Anna Iglseder, Vincent Beliveau, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 20, 2014
(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT
Alexander Kroiss, Barry Lynn Shulkin, Christian Uprimny, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 28, 2013
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma
Alexander Kroiss, Daniel Putzer, Andreas Frech, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 8, 2017
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence
Christian Uprimny, Alexander Stephan Kroiss, Josef Fritz, et al.
Biomedicines
|
November 26, 2022
Imaging Properties and Tumor Targeting of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
Leonhard Gruber, Clemens Decristoforo, Christian Uprimny, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 17, 2025
Safety, Biodistribution, and Radiation Dosimetry of the <sup>68</sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
Elisabeth von Guggenberg, Gianpaolo di Santo, Christian Uprimny, et al.
Page
of 6